GPX-002 / Genprex - LARVOL DELTA

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions (PRNewswire) - "Genprex, Inc...today announced that its research collaborators have been selected to present at the upcoming 2025 American Diabetes Association (ADA) 85th Scientific Session being held June 20-23, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate."

Preclinical • Diabetes • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Genprex Provides Update on Diabetes Gene Therapy Program (PRNewswire) - "Genprex...announced the advancement of its diabetes gene therapy program, including its relationship and collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt). The parties have updated and consolidated the Company's existing license agreements for technologies from Pitt into a new exclusive license agreement for multiple technologies relating to the development of a gene therapy product for both T1D and T2D. Additionally, the Company has formed...Convergen Biotech, Inc., which will focus on the Company's diabetes program development...This license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company's diabetes gene therapy program....Genprex plans to request FDA's guidance for the preclinical studies needed to file an Investigational New Drug (IND) application and initiate first-in-human studies and is poised for FDA Guidance on IND-enabling diabetes studies by the second half of 2025."

Licensing / partnership • Preclinical • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus